Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Rating of “Hold” by Analysts

Sage Therapeutics, Inc. (NASDAQ:SAGE) has received a consensus rating of “Hold” from the nineteen analysts that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, fifteen have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $8.81.

SAGE has been the subject of several research analyst reports. HC Wainwright reaffirmed a “neutral” rating and issued a $12.00 price objective (down previously from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Stifel Nicolaus lowered their price objective on shares of Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating on the stock in a research note on Monday, December 16th. Wedbush reissued a “neutral” rating and set a $6.00 target price on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Bank of America started coverage on Sage Therapeutics in a research note on Tuesday, March 11th. They set an “underperform” rating and a $5.00 price target for the company.

Hedge Funds Weigh In On Sage Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. US Bancorp DE raised its stake in Sage Therapeutics by 22.3% during the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 2,268 shares during the period. Teacher Retirement System of Texas boosted its position in shares of Sage Therapeutics by 21.6% in the fourth quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 2,446 shares during the period. Picton Mahoney Asset Management grew its holdings in shares of Sage Therapeutics by 126.0% during the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 3,581 shares in the last quarter. Geode Capital Management LLC raised its position in Sage Therapeutics by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock valued at $8,975,000 after buying an additional 3,757 shares during the period. Finally, ProShare Advisors LLC lifted its stake in Sage Therapeutics by 31.2% in the 4th quarter. ProShare Advisors LLC now owns 18,281 shares of the biopharmaceutical company’s stock worth $99,000 after acquiring an additional 4,350 shares in the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Trading Up 0.7 %

Shares of NASDAQ:SAGE opened at $8.66 on Friday. The firm’s 50 day moving average is $7.45 and its two-hundred day moving average is $6.73. The firm has a market capitalization of $532.43 million, a P/E ratio of -1.31 and a beta of 0.82. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $19.34.

Sage Therapeutics (NASDAQ:SAGE) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. Analysts predict that Sage Therapeutics will post -3.52 EPS for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.